Milestone Pharmaceuticals is trading at $0.76, with a -5.61% change; healthcare-sector weakness may be contributing.
- No new company-specific catalyst was identified for October 13. The latest company announcement, on October 9, reported the first European participant enrolled in its Phase 3 ReVeRA-301 trial.
- Sector context showed XLV down 1.37%, amid pressure from Johnson & Johnson results and drug-pricing concerns.
- Broader indexes were only slightly lower and do not clearly explain the size of the decline.